Venetoclax–Rituximab in Relapsed or Refractory Chronic Lymphocytic LeukemiaJohn F. Seymour, Arnon P. Kater, Tadeusz Robak et al.|New England Journal of Medicine|2018Cited by 907
Long-term Follow-up of Patients with Relapsed or Refractory Non–Hodgkin Lymphoma Treated with Venetoclax in a Phase I, First-in-Human StudyMatthew S. Davids, John F. Seymour, Andrew W. Roberts et al.|Clinical Cancer Research|2021Cited by 69
Venetoclax retreatment of patients with chronic lymphocytic leukemia after a previous venetoclax-based regimenMeghan C. Thompson, Anthony R. Mato, Rosemary Harrup et al.|Blood Advances|2022Cited by 57
Six-year follow-up and subgroup analyses of a phase 2 trial of venetoclax for del(17p) chronic lymphocytic leukemiaStephan Stilgenbauer, John F. Seymour, Eugen Tausch et al.|Blood Advances|2024Cited by 13